109229
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
确定瑞马唑仑用于内镜逆行胰胆管造影术患者麻醉诱导的中位有效剂量：一项按年龄分层的研究
Authors Meng Y , Song Y, Gao C , Wang S , He K , Xu M
Received 1 May 2025
Accepted for publication 29 October 2025
Published 4 November 2025 Volume 2025:19 Pages 9797—9808
DOI https://doi.org/10.2147/DDDT.S537897
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 5
Editor who approved publication: Professor Anastasios Lymperopoulos
Yan Meng, Youping Song, Chen Gao, Sheng Wang, Keqiang He, Min Xu
Department of Anesthesiology, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, People’s Republic of China
Correspondence: Min Xu, Email seumexumin@163.com Keqiang He, Email doctorhector@ustc.edu.cn
Background: Endoscopic Retrograde Cholangiopancreatography (ERCP) requires precise anesthesia control. Remimazolam is ideal for induction due to its rapid onset and minimal cardiorespiratory impact, but its optimal dose across ages is unclear. This study determined the median effective dose (ED50) of remimazolam for ERCP induction and assessed the influence of age.
Methods: In this prospective study, 110 patients aged 50– 89 years (ASA I–III, BMI 18– 30 kg/m2) scheduled for ERCP were stratified into four age groups: R1 (50– 59), R2 (60– 69), R3 (70– 79), and R4 (80– 89). The Dixon up-and-down method was used, with the initial dose for R1 set at 0.1 mg/kg remimazolam and sequentially reduced by 0.01 mg/kg for the first patient in each older group. Patients received 0.1 μg/kg sufentanil prior to the intravenous administration of a predetermined dose of remimazolam. Anesthesia success was defined as a Modified Observer’s Assessment of Alertness/Sedation (MOAA/S) score of 0 at 3 minutes after intravenous remimazolam administration, which served as the endpoint for determining the effective induction dose.
Results: To determine the effective dose for inducing anesthesia, the ED50 of remimazolam were calculated for groups R1 to R4 as follows: 0.122, 0.108, 0.093, and 0.078 mg/kg, respectively. Similarly, the dosage required to achieve ED95 for the same groups was determined to be 0.132, 0.122, 0.113, and 0.090 mg/kg.Bivariate and multivariable linear regression analyses confirmed a significant inverse correlation between age and remimazolam dose requirement (r = − 0.829, p < 0.001), with age remaining an independent predictor after adjusting for confounders.
Conclusion: This study confirms a significant and independent inverse correlation between age and the required induction dose of remimazolam for ERCP. The ED50 decreases progressively with advancing age. We recommend a tailored reduction in the remimazolam induction dose for geriatric patients to enhance safety.
Keywords: remimazolam, endoscopic retrograde cholangiopancreatography, median effective dose, age-stratified
Department of Anesthesiology, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, People’s Republic of China
Correspondence: Min Xu, Email seumexumin@163.com Keqiang He, Email doctorhector@ustc.edu.cn
Background: Endoscopic Retrograde Cholangiopancreatography (ERCP) requires precise anesthesia control. Remimazolam is ideal for induction due to its rapid onset and minimal cardiorespiratory impact, but its optimal dose across ages is unclear. This study determined the median effective dose (ED50) of remimazolam for ERCP induction and assessed the influence of age.
Methods: In this prospective study, 110 patients aged 50– 89 years (ASA I–III, BMI 18– 30 kg/m2) scheduled for ERCP were stratified into four age groups: R1 (50– 59), R2 (60– 69), R3 (70– 79), and R4 (80– 89). The Dixon up-and-down method was used, with the initial dose for R1 set at 0.1 mg/kg remimazolam and sequentially reduced by 0.01 mg/kg for the first patient in each older group. Patients received 0.1 μg/kg sufentanil prior to the intravenous administration of a predetermined dose of remimazolam. Anesthesia success was defined as a Modified Observer’s Assessment of Alertness/Sedation (MOAA/S) score of 0 at 3 minutes after intravenous remimazolam administration, which served as the endpoint for determining the effective induction dose.
Results: To determine the effective dose for inducing anesthesia, the ED50 of remimazolam were calculated for groups R1 to R4 as follows: 0.122, 0.108, 0.093, and 0.078 mg/kg, respectively. Similarly, the dosage required to achieve ED95 for the same groups was determined to be 0.132, 0.122, 0.113, and 0.090 mg/kg.Bivariate and multivariable linear regression analyses confirmed a significant inverse correlation between age and remimazolam dose requirement (r = − 0.829, p < 0.001), with age remaining an independent predictor after adjusting for confounders.
Conclusion: This study confirms a significant and independent inverse correlation between age and the required induction dose of remimazolam for ERCP. The ED50 decreases progressively with advancing age. We recommend a tailored reduction in the remimazolam induction dose for geriatric patients to enhance safety.
Keywords: remimazolam, endoscopic retrograde cholangiopancreatography, median effective dose, age-stratified